PT-141 (Bremelanotide) Side-Effect Reports from Real Users

What the Clinical Trials Actually Showed

The best controlled data on bremelanotide side effects comes from the two phase III RECONNECT trials, which enrolled 1,247 premenopausal women with hypoactive sexual desire disorder (HSDD) and randomized them to 1.75 mg subcutaneous bremelanotide or placebo for 24 weeks 1.

Nausea Dominated the Adverse-Event Profile

In pooled RECONNECT data, 40.0% of bremelanotide-treated women reported nausea versus 1.3% on placebo 1. That 40% figure is unusually high for an on-demand medication, and it explains why nausea dominates nearly every user forum thread about PT-141.

Other Frequent Events

Flushing occurred in 20.3% of active-treatment participants, headache in 11.3%, and injection-site reactions in 5.4% 1. A transient, dose-dependent rise in systolic blood pressure (mean increase of roughly 2 to 3 mmHg, peaking 2 to 4 hours post-dose) was observed, leading the FDA to contraindicate bremelanotide in patients with uncontrolled hypertension or known cardiovascular disease 2. Discontinuation due to adverse events ran at 13.2% vs. 1.9% for placebo, with nausea driving the majority of dropouts 1.

What the Numbers Mean for a Single Dose

Because bremelanotide is used on-demand rather than daily, the per-dose risk profile matters more than cumulative exposure. A 40% nausea rate does not mean every injection causes nausea. Many trial participants reported nausea only with the first one or two doses, with attenuation over time. The FDA label notes that only 1.4% of participants who experienced nausea rated it as severe 2.

What Reddit Users Report

Reddit threads across r/peptides, r/Trt, r/NootropicsDepot, and r/sexover30 contain hundreds of anecdotal reports on PT-141 side effects. These threads skew heavily toward off-label male users (for erectile dysfunction), a population not studied in the key trials, so the experience can differ from the approved female HSDD indication.

Nausea: The Universal Complaint

Across nearly every Reddit thread discussing PT-141, nausea is mentioned first. One frequently cited pattern: users report that the first injection produces moderate-to-strong nausea lasting 1 to 3 hours, while subsequent doses trigger progressively less. Several users describe taking 8 mg ondansetron (Zofran) 30 minutes before injection to blunt the nausea, though this is not an FDA-recommended approach.

A smaller subset reports nausea severe enough to abandon the drug after a single use. This aligns with the RECONNECT discontinuation data showing nausea as the primary reason participants stopped treatment.

Flushing and Skin Darkening

Facial flushing and a "sunburn-like" warmth across the cheeks and ears are common descriptions. A less frequent but notable report involves gradual skin darkening (hyperpigmentation), particularly with repeated dosing. This is pharmacologically expected: bremelanotide acts on melanocortin-4 receptors, and melanocortin-1 receptor cross-activation stimulates melanogenesis 3. The FDA label lists this as a known risk, especially with cumulative exposure 2.

Dose Experimentation and Its Consequences

Because many male users obtain PT-141 from compounding pharmacies or peptide vendors rather than using the FDA-approved Vyleesi autoinjector (approved only for women), dose ranges reported online vary wildly, from 0.5 mg to 4.0 mg or higher. Users injecting above 2.0 mg consistently report more intense nausea, longer flushing duration, and more pronounced blood pressure symptoms. This dose-response pattern matches preclinical and phase II data showing a clear escalation in adverse events above 1.75 mg 4.

What Drugs.com and Patient Review Sites Show

Drugs.com user reviews for bremelanotide (Vyleesi) show an average rating of approximately 5.0 out of 10 across the reviews posted as of early 2026, with a bimodal distribution: users tend to rate it either very high (8 to 10) or very low (1 to 3).

The Positive Reviews

High-scoring reviews typically acknowledge nausea but describe it as tolerable and worth the benefit. These users report onset of desire within 45 to 90 minutes, lasting 6 to 12 hours, which matches the pharmacokinetic profile (Tmax of approximately 1 hour, terminal half-life of 2.7 hours, but downstream neurochemical effects persisting longer) 2.

The Negative Reviews

Low-scoring reviews cluster around three complaints: (1) nausea severe enough to override any benefit, (2) lack of perceived efficacy, and (3) cost. Side-effect-specific negative reviews often describe a combination of nausea, facial flushing, and a "heavy" or "foggy" feeling that interferes with the intended sexual experience rather than enhancing it.

Selection Bias Matters

Patient review platforms attract users with strong opinions. A person who tried bremelanotide, experienced mild nausea, had a moderately positive result, and moved on is unlikely to write a review. The data is non-random, uncontrolled, and unverifiable. Treat these reports as signals about what side effects bother people most, not as reliable incidence estimates.

Blood Pressure: The Side Effect Clinicians Watch Most

While nausea gets the most user attention, the transient blood pressure elevation is the side effect that carries the most clinical weight 2.

What the Data Shows

In the RECONNECT trials, bremelanotide produced a mean increase in systolic blood pressure of approximately 2 to 3 mmHg and diastolic blood pressure of approximately 1.5 to 2 mmHg, peaking 2 to 4 hours after injection. In most healthy premenopausal women, this change is clinically insignificant. But for off-label users with pre-existing hypertension, cardiovascular disease, or concurrent use of antihypertensives, the interaction space becomes more complex.

Why the FDA Added a Contraindication

The Endocrinologic and Metabolic Drugs Advisory Committee reviewed ambulatory blood pressure monitoring data and concluded that, in patients with uncontrolled hypertension, the transient pressor effect could pose a meaningful risk 2. The FDA's resulting contraindication is straightforward: do not use bremelanotide in patients with uncontrolled hypertension or known cardiovascular disease.

What Users Describe

Online reports of blood pressure effects are less common than nausea reports, likely because most users do not measure their blood pressure after injection. When mentioned, users describe "feeling my heart beat faster," lightheadedness upon standing, or a "pressure in my head." These descriptions are consistent with mild sympathomimetic activation but are not specific enough to confirm a blood pressure mechanism.

Injection-Site Reactions and Practical Complaints

Subcutaneous injection of bremelanotide is not technically difficult, but it generates a category of side effects that oral medications avoid entirely 2.

Bruising and Redness

Forum users frequently post about injection-site bruising, particularly when injecting into the abdomen. Some report a small, firm nodule at the injection site that resolves over 48 to 72 hours. These reactions are typical of subcutaneous peptide injections and are not unique to bremelanotide.

Cold-Chain Complaints

Users sourcing PT-141 from compounding pharmacies sometimes report inconsistent potency, which they attribute to shipping without adequate cold-chain management. While this is not a side effect of the drug itself, it affects the real-world user experience and may explain some reports of "it didn't work" followed by "it worked too well" when the same user tries a different batch. The FDA-approved Vyleesi autoinjector is stored at room temperature, avoiding this issue 2.

Timing Frustration

Multiple forum threads describe frustration with the 45- to 60-minute onset window. Users who inject too close to the intended sexual encounter report that nausea peaks at the worst possible time. The practical recommendation that appears repeatedly in user communities: inject at least 60 minutes before anticipated activity, and have a light meal 30 minutes beforehand to buffer gastric irritation.

Off-Label Male Use: A Different Side-Effect Field

Bremelanotide is FDA-approved only for premenopausal women with HSDD. Yet a substantial portion of online discussion comes from men using it off-label for erectile dysfunction, often sourced from research peptide suppliers rather than pharmacies 5.

What Phase II Male Data Showed

A phase II study of bremelanotide in men with erectile dysfunction (N=342) showed statistically significant improvements in erectile function versus placebo but also demonstrated the same nausea and blood pressure signals seen in women 4. The intranasal formulation tested in early male trials was abandoned after ambulatory blood pressure monitoring revealed larger pressor effects than the subcutaneous route 6.

Forum-Reported Male Side Effects

Male users on Reddit and peptide forums report the same core side-effect trio: nausea, flushing, and a "warm" or "feverish" sensation. Some additionally describe yawning episodes (a known melanocortin pathway effect), fatigue the day after use, and decreased appetite lasting 12 to 24 hours. A minority report nasal congestion, which may be a vascular effect related to the same mechanism that produces flushing.

Dose Matters More Than Anything

The single strongest predictor of side-effect severity in user reports is dose. Users who start at 0.5 mg to 1.0 mg and titrate upward consistently report milder side effects than those who begin at 1.75 mg or above. This observation aligns with the dose-response curves from clinical development, where the 1.75 mg dose was selected as the best balance of efficacy and tolerability 1.

How to Interpret Anecdotal Reports

Online side-effect reports serve a specific and limited function. They reveal which adverse events bother real people the most, highlight practical challenges that clinical trials may not capture (like timing of injection relative to a sexual encounter), and surface rare events that small trials might miss.

What They Cannot Do

They cannot establish incidence rates, identify causation, or control for confounders. A Reddit user who injects PT-141 after drinking three glasses of wine and reports severe nausea may be experiencing a drug-alcohol interaction, alcohol-induced nausea, or both. There is no way to distinguish these scenarios from a forum post.

A Practical Framework

The Endocrine Society has emphasized the importance of shared decision-making in prescribing therapies for sexual dysfunction, noting that patient-reported outcomes and tolerability preferences should inform treatment selection 7. For bremelanotide specifically, this means discussing the high probability of nausea (especially with the first dose), the transient nature of most side effects, the blood pressure contraindication, and the practical timing considerations that make or break the user experience.

Patients who are considering bremelanotide should know that 40% of women in controlled trials experienced nausea, 20% experienced flushing, and 13% discontinued because of adverse events 1. For those who tolerate the first two or three doses, the side-effect profile often improves. The approved dose is 1.75 mg subcutaneous, no more than once per 24 hours and no more than 8 doses per month 2.